Black checkmark with a sparkle and a curved line underneath on a white background.
Company

PepGen Inc.

Ticker
PEPG
Sector
Industry
Report date
November 10, 2026
Valye AI Score

91

Very high visibility
Recent developments
Recent developments summary

Recent news highlights PepGen's clinical progress, analyst coverage, and stock price movements. Multiple analysts maintain buy or outperform recommendations. The company set a DM1 splicing correction record and experienced a recent stock price decline with discussion of a potential trend reversal.

Recent developments:
  • HC Wainwright & Co. maintained a Buy recommendation on PepGen in November and October 2025 [N5][N6].
  • Wedbush maintained an Outperform recommendation in September and October 2025 [N7].
  • Stifel maintained a Buy recommendation in September 2025 [N5].
  • Oppenheimer initiated coverage of PepGen with an Outperform recommendation in February 2026 [N2].
  • PepGen set a DM1 splicing correction record, highlighting clinical progress in September 2025 [N5].
  • PepGen's stock lost 14.3% over four weeks as of May 2026, with analysis suggesting a potential trend reversal [N1].
Overview

PepGen Inc. focuses on developing RNA-targeted therapies for genetic diseases, with its lead candidate PGN-EDODM1 in clinical trials for myotonic dystrophy type 1 (DM1). The company operates primarily in research and development, clinical trial execution, and preparing for potential commercialization. It has no approved products or revenue streams and relies on capital markets to fund operations. PepGen's proprietary EDO platform underpins its therapeutic approach. The company has raised significant capital through private placements, IPO, and public offerings to support ongoing clinical development and operational expenses.

Executive summary

PepGen Inc. is a clinical-stage biotech company developing PGN-EDODM1 for myotonic dystrophy type 1 using its proprietary EDO platform. The company has no approved products or revenue and has incurred significant losses. As of September 30, 2026, PepGen held $21.96 million in cash and $82.85 million in short-term investments, with a strong liquidity position reflected in an 8.7 current ratio. The company is advancing clinical trials and faces typical biotech risks including regulatory, clinical, manufacturing, and capital-raising challenges. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for PEPG

Bull case model:

PepGen's lead candidate PGN-EDODM1 has advanced into Phase 2 clinical trials with ongoing FREEDOM and FREEDOM2 studies, demonstrating clinical progress in a rare disease area with high unmet need. The company has secured substantial funding and maintains strong liquidity ratios, supporting continued development. Positive analyst coverage and recent clinical data milestones, including setting a DM1 splicing correction record, contribute to a constructive view of its potential to develop a novel therapeutic option for DM1 patients.

Bear case model:

PepGen has no approved products and has incurred significant losses since inception, with ongoing high cash burn and the need for additional capital to sustain operations. Clinical development risks include trial delays, adverse events, and regulatory uncertainties. Manufacturing scale-up and commercialization capabilities are unproven. Failure to obtain marketing approval or to secure sufficient funding could materially harm the company's business and prospects. Competition from other therapies and challenges in intellectual property protection add to the risks.

Moat:

PepGen's moat is based on its proprietary EDO platform technology and its lead clinical-stage product candidate PGN-EDODM1 targeting DM1, a rare genetic disorder with unmet medical needs. The company's intellectual property portfolio and clinical progress in a specialized therapeutic area provide barriers to entry. However, the biotech sector's inherent risks, including regulatory hurdles and competition from other RNA-targeted therapies, limit the moat's breadth and durability.

Risks overview
Risks summary
The biggest risk for PepGen is the uncertainty inherent in clinical development and regulatory approval of its lead product candidate, combined with the need for substantial additional capital to sustain operations and advance commercialization.
Risks details:

• Clinical Development Risk: PepGen's success depends on timely and successful completion of clinical trials for PGN-EDODM1, including FREEDOM and FREEDOM2 studies. Delays, adverse events, or failure to demonstrate efficacy and safety could materially harm the business [S1].
• Regulatory Approval Risk: Obtaining marketing approval from FDA, EMA, or other authorities is uncertain and may involve delays or additional requirements. Failure to secure approval would impede commercialization [S1].
• Financial Risk: The company has incurred significant losses and expects to continue doing so. It requires substantial additional funding to advance clinical programs and commercialization. Inability to raise capital on acceptable terms could force delays or cessation of operations [S1][S2].
• Manufacturing and Commercialization Risk: PepGen must establish scalable manufacturing and commercial infrastructure. Challenges in supply chain, manufacturing scale-up, or market acceptance could adversely affect business outcomes [S1].
• Competition and Intellectual Property Risk: Competition from other therapies and potential challenges to intellectual property rights could limit market opportunities and affect profitability [S1].

FINAL FORECAST FOR PEPG

Final take one line
PepGen Inc. is a clinical-stage biotech company with very high visibility into its development programs, financial position, and risks, advancing RNA-targeted therapies for DM1 with ongoing clinical trials and strong liquidity as of late 2026.
Final take 12 to 24 month view

Business trends: Continued clinical development of PGN-EDODM1 with ongoing FREEDOM trials and advancing proprietary EDO platform; increasing operational expenses aligned with clinical and regulatory activities.
Execution milestones: Completion of FREEDOM2 data readouts; securing regulatory approvals; establishing manufacturing scale-up and commercial infrastructure; raising additional capital as needed.
Key risks: Clinical trial and regulatory uncertainties; capital raising challenges; manufacturing and commercialization execution; competition and intellectual property protection.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

91
LLM visibility overview
LLM Visibility known facts
  • PepGen Inc. is a clinical-stage biotechnology company focused on developing therapies using its proprietary EDO platform, primarily targeting myotonic dystrophy type 1 (DM1) with its lead product candidate PGN-EDODM1 [S1].
  • The company has no products approved for commercial sale and has not generated revenue from product sales to date [S1].
  • PepGen's lead candidate PGN-EDODM1 is in clinical development, including ongoing FREEDOM and FREEDOM2 clinical trials [S1].
  • The company is dependent on the successful completion of clinical trials, regulatory approvals, manufacturing scale-up, and commercial acceptance of PGN-EDODM1 [S1].
  • PepGen has incurred significant operating losses since inception, with net losses of approximately $89.7 million for the year ended December 31, 2025, and an accumulated deficit of $361.1 million as of that date [S1].
  • As of September 30, 2026, PepGen reported cash and cash equivalents of $21.96 million and short-term investments of $82.85 million, totaling $104.41 million in liquid assets [S2].
  • The company had current assets of $107.57 million and current liabilities of $12.36 million as of September 30, 2026, resulting in a strong current ratio of 8.7 and a cash ratio of 8.48, indicating solid short-term liquidity [S2].
  • PepGen expects to incur increasing expenses related to clinical development, manufacturing scale-up, regulatory activities, and potential commercialization efforts [S1].
  • The company has raised substantial capital through private placements, IPO, ATM programs, and public offerings, with net proceeds of $107.6 million from a 2025 offering [S1].
  • PepGen faces risks including clinical trial delays, regulatory uncertainties, manufacturing challenges, competition, intellectual property protection, and the need for additional capital [S1].
  • Recent analyst coverage includes multiple buy and outperform recommendations from firms such as HC Wainwright, Wedbush, Stifel, and Oppenheimer [N2][N5][N6][N7].
  • News coverage highlights PepGen's clinical progress, including setting a DM1 splicing correction record, and notes recent stock price volatility with a 14.3% decline over four weeks but potential for trend reversal [N1][N5][N9].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-04 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-05-20 | www.nasdaq.com | PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner | https://www.nasdaq.com/articles/pepgen-pepg-loses-143-4-weeks-heres-why-trend-reversal-may-be-around-corner
  • N2 | 2026-02-25 | www.nasdaq.com | Oppenheimer Initiates Coverage of PepGen (PEPG) with Outperform Recommendation | https://www.nasdaq.com/articles/oppenheimer-initiates-coverage-pepgen-pepg-outperform-recommendation
  • N3 | 2025-12-10 | www.nasdaq.com | How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44% | https://www.nasdaq.com/articles/how-much-upside-left-pepgen-pepg-wall-street-analysts-think-7544
  • N4 | 2025-11-25 | www.nasdaq.com | Sarepta's Stock Rises on Positive Updates on DM1 Therapy | https://www.nasdaq.com/articles/sareptas-stock-rises-positive-updates-dm1-therapy
  • N5 | 2025-11-14 | www.nasdaq.com | HC Wainwright & Co. Maintains PepGen (PEPG) Buy Recommendation | https://www.nasdaq.com/articles/hc-wainwright-co-maintains-pepgen-pepg-buy-recommendation-1
  • N6 | 2025-10-28 | www.nasdaq.com | HC Wainwright & Co. Maintains PepGen (PEPG) Buy Recommendation | https://www.nasdaq.com/articles/hc-wainwright-co-maintains-pepgen-pepg-buy-recommendation-0
  • N7 | 2025-10-01 | www.nasdaq.com | Wedbush Maintains PepGen (PEPG) Outperform Recommendation | https://www.nasdaq.com/articles/wedbush-maintains-pepgen-pepg-outperform-recommendation-0
  • N8 | 2025-10-01 | www.nasdaq.com | Biotech Stocks Rebound After Hours Amid Broader Sector Tailwinds | https://www.nasdaq.com/articles/biotech-stocks-rebound-after-hours-amid-broader-sector-tailwinds
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine